October 2026 Premarket Approval (PMA) Authorizations

The U.S. Food and Drug Administration (FDA) recorded 221 Premarket Approval (PMA) regulatory decisions during October 2026, including three original PMA approvals and 218 supplemental approvals or 30-day notice decisions, according to an analysis by Medical Devices and Pharma (MDP).

Although new medical device approvals often receive the greatest attention, October’s data illustrates another important aspect of medical device regulation: the substantial regulatory activity that continues throughout a device’s commercial life.

MDP’s October 2026 FDA PMA Approvals Report examines original approvals, supplemental submission pathways, FDA advisory committee activity, manufacturing changes, applicant activity, and regulatory decision timing.

Three Medical Devices Receive Original PMA Approval

Three original PMA approvals were recorded during October.

These approvals represent new authorizations through FDA’s PMA pathway, generally applicable to Class III medical devices requiring the highest level of regulatory review.

Unlike the 510(k) pathway, which generally relies on demonstrating substantial equivalence to a legally marketed predicate device, PMA requires valid scientific evidence providing reasonable assurance of safety and effectiveness for the device’s intended use.

The three October approvals illustrate continued innovation in cardiovascular and related medical technologies.

Most PMA Activity Involves Previously Approved Devices

Of the 221 October decisions, 218 involved PMA supplements or 30-day notices, representing approximately 98.6% of all recorded activity.

The distribution of regulatory pathways included:

The three original PMA approvals bring the monthly total to 221. Notably, 30-day notices accounted for 67.9% of all October PMA decisions.

These notices are generally associated with certain manufacturing changes that affect the safety or effectiveness of an approved device. They are distinct from original PMA approvals and should not be interpreted as newly authorized medical devices.

Manufacturing and Process Changes Dominate Regulatory Activity

Perhaps the most significant finding concerns the reasons manufacturers submitted PMA supplements and notices. Of the 218 supplemental and notice decisions, 158 involved manufacturing, sterilization, packaging, or supplier process changes. That represents 72.5% of all supplement and notice activity.

Other regulatory changes included:

• Design, component, specification, or material changes: 28 decisions.
• Postapproval study-related activity: 14 decisions.
• Labeling changes: 13 decisions.
• Manufacturing location changes: four decisions.
• Postapproval study-related labeling: one decision.

These findings highlight the extensive regulatory responsibilities associated with maintaining approved medical devices. Manufacturers must continually evaluate changes to production processes, materials, suppliers, equipment, and manufacturing facilities to determine whether FDA notification or approval is required.

For quality and regulatory professionals, this activity underscores the importance of effective design and process change control, supplier management, risk management, and regulatory impact assessments. A device’s original PMA approval establishes its authorization for marketing, but subsequent changes can create additional regulatory obligations throughout its lifecycle.

Cardiovascular Devices Account for More Than Half of PMA Decisions

October’s PMA activity was concentrated in several medical specialties.

Cardiovascular devices accounted for more than half of all PMA decisions, reflecting substantial regulatory activity involving cardiac implants, vascular devices, and related technologies. Neurology and ophthalmic devices were also prominent.

These figures reflect FDA advisory committee classifications and include both original approvals and lifecycle decisions. They should not be interpreted as the number of newly approved devices within each specialty.

Regulatory Activity Extends Across Major Manufacturers

October’s dataset included activity involving established medical device manufacturers such as Biotronik, Abbott, Medtronic, and Edwards Lifesciences.

Many decisions involved modifications to existing device families rather than entirely new technologies. This distinction is important when interpreting manufacturer activity. A company with numerous PMA supplement decisions is not necessarily introducing an equivalent number of new devices.

Instead, the activity may reflect ongoing improvements, manufacturing modifications, supplier changes, or other regulatory maintenance of existing product portfolios.

Understanding PMA Review Timing

MDP also examined elapsed calendar time between FDA’s recorded receipt and decision dates for the different PMA submission pathways. These measurements provide insight into the timing associated with regulatory decisions, but they should not be confused with official FDA review-clock performance.

Elapsed calendar time may include periods when FDA is awaiting additional information from manufacturers, administrative processing, or other activities not counted toward statutory review goals.

The report provides additional analysis of decision timing across the various PMA pathways.

What October’s PMA Activity Tells Us

October’s results demonstrate that FDA’s PMA program involves considerably more than evaluating new Class III medical devices.

While three original approvals introduced newly authorized technologies, the overwhelming majority of recorded regulatory decisions involved previously approved products.

The prominence of manufacturing and process changes also illustrates the close relationship between regulatory affairs, quality management, manufacturing operations, and supplier oversight.

For medical device manufacturers, this reinforces a fundamental principle. FDA approval is not the end of the regulatory process. It is the beginning of an ongoing responsibility to maintain device safety, effectiveness, manufacturing controls, and regulatory compliance.

Understanding these lifecycle obligations is essential to sustaining market authorization and managing changes to approved medical devices.

MDP’s comprehensive report provides additional information and analysis, including original PMA approvals and device details, PMA supplement and 30-day notice pathways, FDA advisory committee distribution, manufacturing and regulatory change categories, manufacturer activity, regulatory decision timing, and noteworthy findings and regulatory intelligence observations.

Source: FDA Premarket Approval database, October 2026 decision records. MDP analysis reflects decisions recorded during the reporting period and may be subject to subsequent FDA database updates. This is an independent MDP Regulatory Intelligence publication and is not an official FDA report.

Download the Full October 2026 FDA PMA Approvals Report